⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication or changing your treatment plan.
Millions of Indians with Type 2 Diabetes (T2D) are currently on insulin therapy — either alone or in combination with oral medications like metformin. As GLP-1 receptor agonists (semaglutide/Ozempic and tirzepatide/Mounjaro) become increasingly available in India, many endocrinologists and diabetologists are evaluating whether their insulin-dependent patients could benefit from transitioning to or adding a GLP-1 medication.
This is not a simple switch. The transition from insulin to GLP-1 therapy requires careful medical supervision, blood glucose monitoring, and a clear understanding of the risks — particularly hypoglycaemia during dose crossover.
This guide is for Indian patients and their families to understand the process, ask the right questions, and monitor their health safely during the transition.
India has the world's second largest population of people with diabetes, estimated at 101 million adults (ICMR-INDIAB study, 2023). Many of these patients are on basal insulin (Lantus/glargine, Tresiba/degludec), premix insulin (Mixtard, Novomix), or multiple daily injections.
GLP-1 receptor agonists offer several advantages that make them attractive alternatives or additions to insulin:
Weight loss: Insulin causes weight gain (typically 2–5 kg over the first year). GLP-1 medications cause weight loss of 10–22% depending on the agent. For overweight Indian T2D patients — the majority — this is a significant benefit.
Lower hypoglycaemia risk (as monotherapy): Unlike insulin, GLP-1 medications only stimulate insulin secretion when blood glucose is elevated (glucose-dependent mechanism). As a result, GLP-1 as a standalone therapy has a much lower risk of hypoglycaemia than insulin — though the risk rises when GLP-1 is combined with insulin or sulphonylureas.
Cardiovascular and kidney protection: Semaglutide (LEADER, SUSTAIN-6 trials) and tirzepatide (SURPASS-CVOT) demonstrate cardioprotective and renoprotective effects — particularly valuable for Indian T2D patients with high rates of diabetic nephropathy and coronary artery disease.
Once-weekly injection: Versus once- or twice-daily insulin injections.
Not all insulin-to-GLP-1 transitions are the same. Your doctor may recommend one of three approaches:
This is most appropriate for patients with:
Typical protocol:
This requires daily blood glucose monitoring throughout the transition period.
Some patients remain on insulin but add a GLP-1 for its additional benefits. This is called combination or "basal insulin + GLP-1" therapy. In India, this approach is used in:
Important: When starting GLP-1 alongside insulin, basal insulin dose must be reduced by 20–30% from day one to prevent hypoglycaemia.
As GLP-1 improves insulin sensitivity and promotes weight loss, insulin requirements naturally decrease. This "spontaneous" reduction is the most gradual transition and must be guided by blood glucose monitoring rather than a predetermined schedule.
Before starting:
Week 1 (GLP-1 initiation):
Weeks 2–4 (dose crossover):
Months 2–4 (stabilisation):
Blood glucose targets during transition:
Red flags requiring same-day doctor contact:
What to log in your diary or app (HealthifyMe, mySugr):
Indian dietary patterns: Most Indian T2D patients eat three rice- or roti-heavy meals daily. As GLP-1 reduces appetite, carbohydrate intake drops naturally — which will lower insulin requirements faster than expected. Your doctor must know if you are eating significantly less on GLP-1.
Sulphonylureas: Many Indian T2D patients are prescribed glimepiride or glipizide alongside insulin. When adding GLP-1, sulphonylurea doses must also be reduced — the combination of sulphonylurea + GLP-1 significantly increases hypoglycaemia risk.
Type 1 Diabetes: GLP-1 medications are NOT approved for Type 1 Diabetes. People with T1D must not use GLP-1 as a substitute for insulin — this can cause fatal DKA.
Kidney disease: GLP-1 medications are generally safe in mild-to-moderate CKD (eGFR above 15 mL/min/1.73 m²). However, in advanced kidney disease, dose adjustment and close monitoring are required.
Cost: Ozempic 0.5 mg pre-filled pen costs approximately ₹8,000–₹10,000 per month in India (as of 2025). Mounjaro 5 mg is approximately ₹18,000–₹22,000 per month. Insulin (Lantus/Tresiba with subsidies or generic brands) can be significantly cheaper. Discuss affordability with your doctor before starting.
Not reducing insulin when starting GLP-1. This is the most common and dangerous mistake. Starting GLP-1 without reducing insulin leads to hypoglycaemia as two glucose-lowering agents work simultaneously.
Stopping insulin too abruptly. Some patients, excited about GLP-1's effectiveness, stop insulin themselves without medical guidance. This can cause severe hyperglycaemia, particularly if GLP-1 dose is still low in early titration weeks.
Not monitoring blood glucose daily. The transition period is when monitoring matters most. Many Indian patients check glucose only weekly — this is insufficient during a medication change.
Eating much less without telling the doctor. GLP-1 significantly reduces food intake. If you are eating 40–50% less than before and your insulin dose hasn't been reduced to match, you will have hypoglycaemia.
Q: Can I switch from insulin to GLP-1 on my own?
No. The switch requires a prescribing physician who will adjust your insulin doses and monitor your blood glucose. Self-managing this transition is dangerous.
Q: Will I still need insulin after starting GLP-1?
It depends on how long you have had T2D and how much insulin-producing capacity your pancreas retains. Many patients with T2D of less than 10 years duration can reduce or eliminate basal insulin on GLP-1. Those with longer disease duration or significant beta-cell failure may still require some insulin.
Q: My doctor in a small town has not prescribed GLP-1 before. What should I do?
Ask for a referral to an endocrinologist in the nearest city. Apollo, Fortis, and Max hospitals in most Indian metros have endocrinology departments. Telemedicine platforms like Practo also connect patients with GLP-1-experienced endocrinologists.
Q: How long does the full transition take?
Typically 8–16 weeks for a complete switch from basal insulin to GLP-1 monotherapy. If transitioning to combination therapy, there is no fixed end point — insulin requirements are adjusted on an ongoing basis.
Consult your healthcare provider before starting any medication. This article is for informational purposes only and does not replace advice from a licensed medical professional.
